Best change in BM blasts, duration of remission, and OS in patients receiving flotetuzumab immunotherapy. (A) Fifty patients treated at the RP2D differentiated by AML status at study entry: 45 response-evaluable, 40 patients in waterfall plot, 5 progressive disease (PD) on peripheral blood blasts; nonevaluable patients, 5: 2 patients withdrew consent, 3 patients withdrawn due to non-TRAEs. AML status at study entry and percentage of BM blasts at baseline are indicated. (B) Eight PIF/ER AML patients treated at RP2D who achieved a response on flotetuzumab. Median time to best response represented in red (median, 0.8 months; range, 0.8-2.1 months) and duration of response in blue (median, 9.1 months; range, 1.1-26.4 months). Purple depicts OS beyond relapse. *BM aspirate for this patient was hemodiluted but immunohistochemistry on BM formalin-fixed paraffin embedded confirmed the percent blast. ☆, Time at which patients underwent hematopoietic stem cell transplantation (HSCT).